HomepageIMC ā¢ ASX
add
Immuron Ltd
Vorige slotkoers
$Ā 0,077
Jaar-range
$Ā 0,065 - $Ā 0,17
Beurswaarde
17,63Ā mln. AUD
Gem. volume
110,97K
Koers/winst
-
Dividendrendement
-
Primaire beurs
ASX
Marktnieuws
Financiƫle informatie
Resultatenrekening
Opbrengst
Netto inkomsten
(AUD) | jun 2024info | Wijziging j-o-j |
---|---|---|
Opbrengst | 1,27Ā mln. | 108,61% |
Bedrijfskosten | 2,56Ā mln. | 79,40% |
Netto inkomsten | -2,43Ā mln. | -169,00% |
Netto winstmarge | -190,94 | -28,94% |
Winst per aandeel | ā | ā |
EBITDA | -1,68Ā mln. | -118,52% |
Effectief belastingtarief | ā | ā |
Balans
Totale activa
Totale passiva
(AUD) | jun 2024info | Wijziging j-o-j |
---|---|---|
Contanten en kortetermijnbeleggingen | 11,66Ā mln. | -32,07% |
Totale activa | 15,55Ā mln. | -29,28% |
Totale passiva | 2,84Ā mln. | 19,79% |
Totaal aandelenvermogen | 12,71Ā mln. | ā |
Uitstaande aandelen | 228,00Ā mln. | ā |
Koers-boekwaardeverhouding | 1,28 | ā |
Rendement op activa | -27,02% | ā |
Rendement op kapitaal | -32,61% | ā |
Kasstroom
Nettomutatie in liquide middelen
(AUD) | jun 2024info | Wijziging j-o-j |
---|---|---|
Netto inkomsten | -2,43Ā mln. | -169,00% |
Operationele kasstroom | -1,94Ā mln. | -141,79% |
Kasstroom uit beleggingen | 87,03K | 1.082,80% |
Kasstroom uit financiering | 12,00K | 203,57% |
Nettomutatie in liquide middelen | -1,78Ā mln. | -170,36% |
Vrije kasstroom | -1,03Ā mln. | -197,20% |
Over
Immuron is a biotechnology company based in Melbourne, Australia. In 2008, the company changed its name to Immuron Limited, having previously operated as Anadis Limited.
Immuron is focused on antigen-primed and dairy-derived health products. Its proprietary technologies allow for rapid development of polyclonal antibody and other proteins-based solutions for a range of diseases. The company specialises in nutraceutical, pharmaceutical and therapeutic technology products for conditions such as oral and GI mucositis, avian influenza, E. coli travellers' diarrhoea and Anthrax containment.
In 2005, Anadis signed an agreement with Quebec's Baralex Inc. and Valeo Pharma Inc. for the distribution of Travelan, a product made by Anadis for the Canadian market. Wikipedia
Opgericht
1994
Hoofdvestiging
Website
Werknemers
7